Virtual Library
Start Your Search
T. Yokoi
Author of
-
+
MA 05 - Immuno-Oncology: Novel Biomarker Candidates (ID 658)
- Event: WCLC 2017
- Type: Mini Oral
- Track: Immunology and Immunotherapy
- Presentations: 1
- Moderators:Yoichi Nakanishi, P. Mitchell
- Coordinates: 10/16/2017, 15:45 - 17:30, Room 303 + 304
-
+
MA 05.06 - Comparison Study of PD-L1 Immunohistochemistry Assays with 22C3 and 28-8: Analysis on Surgical Specimens of NSCLC. (ID 8423)
16:20 - 16:25 | Author(s): T. Yokoi
- Abstract
- Presentation
Background:
The checkpoint inhibitors programmed cell death and its ligand (PD-L1) antibodies are promising treatment agents for patients with advanced non-small cell lung cancer (NSCLC). Their clinical efficacy is predicted by drug-tailored PD-L1 immunohistochemistry (IHC) assays. We aimed to identify the similarity and distinction of 22C3 and 28-8 IHC tests.
Method:
Three hundred and ninety consecutive cases of completely resected NSCLC between January 2009 and September 2014 that had adequate tissue samples were investigated. From the archived samples, 5-μm thick sections were cut and stained with PD-L1 IHC 22C3 PharmDx and 28-8 PharmDx (Dako, Santa Clara, CA). The staining and evaluation in 22C3 and 28-8 test were performed by two separate laboratories. PD-L1 expression and high PD-L1 expression were defined as ≥1% and ≥50% of tumor cells stained, respectively. Statistical significance was defined as a p-value of <0.05.
Result:
The study population included 288 patients with adenocarcinomas, 70 with squamous cell carcinomas, 18 with large cell carcinomas, 9 with adenosquamous carcinoma and 5 with pleomorphic carcinoma. Two hundred and ninety-three patients had pStage I; 47, pStage II; and 46, p Stage IIIA tumors. Two hundred and twenty-nine specimens showed no PD-L1 expression with either 22C3 or 28-8. The detection rate of PD-L1 expression was 36.9% (144 cases) with 22C3 and 35.6% (139 cases) with 28-8, respectively (p= 0.710). The detection rate of high PD-L1 expression was 16.9% (66 cases) with 22C3 and 9.0% (35 cases) with 28-8 (p= 0.0013). The Spearman correlation coefficient was 0.866 (95% confidence interval, 0.838–0.890; p< 0.0001). Figure 1
Conclusion:
22C3 IHC assay may be more sensitive to detect high PD-L1 expression in NSCLC compard to 28-8 IHC assay, whereas 22C3 and 28-8 showed no significant difference to detect PD-L1 expression. Further investigation is necessary to reveal clinical, pathological and molecular background. This approach will help better interpretation of PD-L1 IHC results.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P2.09 - Mesothelioma (ID 710)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Mesothelioma
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.09-005a - Clinical Characteristics of Early Stage, Malignant Pleural Mesothelioma (ID 10043)
09:30 - 09:30 | Author(s): T. Yokoi
- Abstract
Background:
While the mortality rate has markedly improved for primary lung cancer, a disease that used to be incredibly difficult to treat, the prognosis for malignant pleural mesothelioma (MPM) is as poor as ever, with a mean survival time (MST) after diagnosis of about 1 year. Therefore, it is thought that the most practical method of obtaining better survival times than those associated with currently available treatment options is diagnosing MPM at an earlier stage than is possible now. We performed a retrospective study to evaluate the clinical characteristics of early stage MPM.
Method:
The study included 83 patients with a definitive MPM diagnosis of International Mesothelioma Interest Group (IMIG) clinical stage T0-1a/1bN0M0. We selected 40 patients who did not exhibit significant fluorodeoxyglucose (FDG) accumulation (<2.5) in FDG-positron-emission tomography (PET) prior to starting treatment, and then retrospectively examined their clinical characteristics.
Result:
There were 4 women in this study, 5 patients with no history of asbestos exposure, 37 patients with epithelial histology, 3 patients with biphasic histology, and 3 patients with negative cytology. All patients had pleural effusion.
Conclusion:
Although this was a retrospective study, we found that among T0-1a/1bN0M0 and PET-negative MPM patients, positive cytology (class IV/V) and histology (biphasic) were factors associated with a poor prognosis.
